Product Information
PIOGLITAZONE-METFORMIN 15-850 is a generic product labeled by Macleods Pharmaceuticals Limited, priced at $0.2391 per EA under NDC 33342017709. Its NADAC has been published 486 times since Jun 14, 2017.
FDA first approved this application on Nov 5, 2015. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
850; 15 mg/1; mg/1
Manufacturer
Macleods Pharmaceuticals LimitedNDC
33342017709
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA204802FDA Approved
11/5/2015
TE Code
AB
On Market Since
11/6/2015
Pharmacological Classes
Price Statistics
The NADAC for PIOGLITAZONE-METFORMIN 15-850 has been published 486 times since Jun 14, 2017, and over the history we have for it it has declined 82.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2391 per EA |
|---|---|
| All-time high | $1.3399 (Jun 14, 2017) |
| All-time low | $0.2180 (May 22, 2024) |
| 52-week high | $0.3035 |
| 52-week low | $0.2391 |
| Median price | $0.4966 |
| Average price | $0.5480 |
| Largest weekly change | -54.8% (Sep 20, 2023) |
| Weeks tracked | 486 |
| Tracking since | Jun 14, 2017 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Macleods Pharmaceuticals Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Pioglitazone and metformin hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Biguanide class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PIOGLITAZONE-METFORMIN 15-850?
The current National Average Drug Acquisition Cost (NADAC) for PIOGLITAZONE-METFORMIN 15-850, manufactured by Macleods Pharmaceuticals Limited, is $0.2391 per EA (NDC 33342017709), effective Sep 30, 2026.
How has the price of PIOGLITAZONE-METFORMIN 15-850 changed over time?
Over the history we have for it, the NADAC for PIOGLITAZONE-METFORMIN 15-850 has declined 82.2%. It has been tracked across 486 weekly CMS publications since Jun 14, 2017.
What are the highest and lowest recorded NADAC prices for PIOGLITAZONE-METFORMIN 15-850?
Since Jun 14, 2017, the NADAC for PIOGLITAZONE-METFORMIN 15-850 has ranged from a low of $0.2180 (May 22, 2024) to a high of $1.3399 (Jun 14, 2017), with a median of $0.4966 per EA.
Are there cheaper alternatives to PIOGLITAZONE-METFORMIN 15-850?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as PIOGLITAZONE-METFORMIN 15-850 in a comparable dosage form, but none are currently priced below it.
Who manufactures PIOGLITAZONE-METFORMIN 15-850?
PIOGLITAZONE-METFORMIN 15-850 (NDC 33342017709) is labeled by Macleods Pharmaceuticals Limited, and CMS classifies it as a generic product.